Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APn.2
- Development stage
- Preclinical
- Lead developer
- SASPiPhi
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
APn.2 is an engineered bacteriophage-based antibacterial therapy developed by SASPiPhi using the proprietary SASPject platform. It is specifically designed to target and eliminate *Acinetobacter baumannii*, a Gram-negative pathogen frequently associated with multi-drug resistant (MDR) hospital-acquired infections. The SASPject technology utilizes modified bacteriophages as delivery vectors to inject a gene encoding Small Acid-Soluble Spore Proteins (SASP) into the target bacterial cells. Once expressed, these proteins bind non-specifically and saturably to the bacterial DNA, effectively halting DNA replication and transcription. This mechanism leads to rapid bacterial cell death and is independent of the pathogen's existing antibiotic resistance mechanisms. APn.2 is currently in the lead optimization stage of preclinical development.
- Other names
- SASPiPhi-Acinetobacter baumannii-bacteriophage-based therapy (SASPject platform)SASPiPhi-Acinetobacter baumannii-bacteriophage-based therapySASPject Acinetobacter baumannii therapy
02
Targets
DNA
Beyond the preview
Go deeper on APn.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APn.2.